Trial Profile
A Randomized Phase III Study on Maintenance Durvalumab vs Placebo Following Post-operative Concomitant Chemoradiation in Subjects With HPV-negative Squamous Cell Head and Neck Carcinoma (HNSCC) With High Risk of Recurrence
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ADHERE
- 09 Mar 2021 Planned initiation date changed from 1 Mar 2019 to 1 Jun 2021.
- 09 Mar 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Sep 2018 New trial record